Search Results - Linus Backert

  • Showing 1 - 5 results of 5
Refine Results
  1. 1

    Characterization of the Canine MHC Class I DLA-88*50101 Peptide Binding Motif as a Prerequisite for Canine T Cell Immunotherapy. by Sharon M Barth, Christian M Schreitmüller, Franziska Proehl, Kathrin Oehl, Leonie M Lumpp, Daniel J Kowalewski, Moreno Di Marco, Theo Sturm, Linus Backert, Heiko Schuster, Stefan Stevanović, Hans-Georg Rammensee, Oliver Planz

    Published in PLoS ONE (2016-01-01)
    Get full text
    Article


  2. 2

    HLA Ligand Atlas DIA: extending the benign immunopeptidomics resource with increased sensitivity through data-independent acquisition mass spectrometry by Michael Weller, Roland Martin, Holger Moch, Luca Regli, Hans-Georg Rammensee, Linus Backert, Oliver Kohlbacher, Juliane S Walz, Ana Marcu, Leon Bichmann, Daniel Johannes Kowalewski, Lena Katharina Freudenmann, Lena Mühlenbruch, Maren Lübke, Philipp Wagner, Tobias Engler, Sabine Matovina, Mathias Hauri-Hohl, Markus W Löffler, Hannes Röst, Marian C Neidert

    Published in Journal for ImmunoTherapy of Cancer (2025-08-01)
    Get full text
    Article


  3. 3

    HLA Ligand Atlas: a benign reference of HLA-presented peptides to improve T-cell-based cancer immunotherapy by Jian Wang, Michael Weller, Roland Martin, Holger Moch, Julia Velz, Luca Regli, Hans-Georg Rammensee, Linus Backert, Oliver Kohlbacher, Ana Marcu, Leon Bichmann, Leon Kuchenbecker, Daniel Johannes Kowalewski, Lena Katharina Freudenmann, Lena Mühlenbruch, András Szolek, Maren Lübke, Philipp Wagner, Tobias Engler, Sabine Matovina, Mathias Hauri-Hohl, Konstantina Kapolou, Juliane Sarah Walz, Manuela Silginer, Markus W. Löffler, Florian Erhard, Andreas Schlosser, Stefan Stevanović, Marian Christoph Neidert

    Published in Journal for ImmunoTherapy of Cancer (2021-04-01)
    Get full text
    Article


  4. 4

    First-in-human dose escalation trial to evaluate the clinical safety and efficacy of an anti-MAGEA1 autologous TCR-transgenic T cell therapy in relapsed and refractory solid tumors by Ignacio I Wistuba, Mamta Kalra, Linus Backert, Martin Wermke, Edwin R Parra, Jason John Luke, Apostolia M Tsimberidou, Sebastian Bunk, Mohammad B Hossain, Andrea Mayer-Mokler, Arun Satelli, Norbert Hilf, Steffen Walter, Cedrik M Britten, Van K Morris, Tobias A W Holderried, Winfried H Alsdorf, Katrin Wetzko, Borje S Andersson, Sandra Grund-Gröschke, Katrin Aslan, Anantha Marisetty, Swapna Satam, Jens Hukelmann, M Alper Kursunel, Karine Pozo, Andreas Acs, Melissa Baumeister, Claudia Wagner, Oliver Schoor, Ali S Mohamed, Delfi Krishna

    Published in Journal for ImmunoTherapy of Cancer (2024-07-01)
    Get full text
    Article


  5. 5

    A new synthetic toll-like receptor 1/2 ligand is an efficient adjuvant for peptide vaccination in a human volunteer by Hans-Georg Rammensee, Karl-Heinz Wiesmüller, P. Anoop Chandran, Henning Zelba, Elisa Rusch, Cécile Gouttefangeas, Daniel J. Kowalewski, Moreno Di Marco, Sebastian P. Haen, Juliane S. Walz, Yamel Cardona Gloria, Johanna Bödder, Jill-Marie Schertel, Antje Tunger, Luise Müller, Maximilian Kießler, Rebekka Wehner, Marc Schmitz, Meike Jakobi, Nicole Schneiderhan-Marra, Reinhild Klein, Karoline Laske, Kerstin Artzner, Linus Backert, Heiko Schuster, Johannes Schwenck, Alexander N. R. Weber, Bernd J. Pichler, Manfred Kneilling, Christian la Fougère, Stephan Forchhammer, Gisela Metzler, Jürgen Bauer, Benjamin Weide, Wilfried Schippert, Stefan Stevanović, Markus W. Löffler

    Published in Journal for ImmunoTherapy of Cancer (2019-11-01)
    Get full text
    Article


Search Tools: